<PAGE> 1
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) January 11, 2001
AAIPHARMA INC.
------------------------------------------------------
(Exact Name of Registrant as Specified in its Charter)
Delaware 0-21185 04-2687849
---------------------------- ------------------------ -------------------
(State or Other Jurisdiction (Commission File Number) (I.R.S. Employer
of Incorporation) Identification No.)
2320 Scientific Park Drive
Wilmington, North Carolina 28405
----------------------------------------
(Address of Principal Executive Offices)
(Zip Code)
(910) 254-7000
----------------------------------------------------
(Registrant's Telephone Number, Including Area Code)
Applied Analytical Industries, Inc.
-----------------------------------------------------
(Former name or address, if changed from last report)
<PAGE> 2
Item 5. Other Events.
On January 11, 2001, aaiPharma Inc., formerly Applied Analytical
Industries, Inc. (the "Company"), issued a press release (the "Release")
concerning the execution of licensing agreement between the Company and Aventis
Pharmaceuticals. The Release is filed as Exhibit 99.1 hereto and is incorporated
by reference herein.
Item 7. Financial Statements and Exhibits.
(a) Exhibits
Exhibit 99.1 -- Press release dated January 11, 2001
2
<PAGE> 3
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Date: January 12, 2001
AAIPHARMA INC.
By: /s/ William L. Ginna, Jr.
--------------------------------
William L. Ginna, Jr.
Executive Vice President and
Chief Financial Officer
EXHIBIT INDEX
Exhibit No. Exhibit
----------- -------
Exhibit 99.1 -- Press release dated January 11, 2001
3
